Artal Group Sa Decreased Acceleron Pharma Inc (Call) (NASDAQ:XLRN) Stake By $36.00 Million

August 13, 2018 - By Darrel Chase

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It improved, as 13 investors sold XLRN shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. Bailard Incorporated reported 0.03% in Acceleron Pharma Inc. (NASDAQ:XLRN). Raymond James & Assoc holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 9,478 shares. Winslow Evans & Crocker holds 0% or 1,616 shares in its portfolio. Sei Invs Communication holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 300 shares. Meeder Asset Mgmt, a Ohio-based fund reported 127 shares. Farallon Cap Limited invested in 0.38% or 1.40 million shares. Utd Services Automobile Association reported 103,861 shares. Bank Of Ny Mellon invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Foresite Cap Ii Limited Liability Co invested in 244,756 shares. 98,050 are owned by Millennium Mgmt Ltd Liability Co. Rhumbline Advisers holds 0% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 36,854 shares. Platinum Investment Mngmt Limited owns 0.06% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 58,500 shares. Prtn Ltd Limited Liability Company holds 64,166 shares. The Connecticut-based Aqr Cap Mgmt Lc has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Pnc Svcs Gp holds 131,119 shares.

Since March 6, 2018, it had 0 insider buys, and 7 sales for $3.31 million activity. MCLAUGHLIN KEVIN F also sold $153,792 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3. Sherman Matthew L sold 4,600 shares worth $176,772. $134,395 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Rovaldi Christopher. 1,204 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $46,232 were sold by Quisel John D. 37,500 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $1.55 million were sold by POPS RICHARD F.

Artal Group Sa decreased its stake in Acceleron Pharma Inc (Call) (NASDAQ:XLRN) by 88.24% based on its latest 2018Q2 regulatory filing with the SEC. Artal Group Sa sold 750,000 shares as the company’s stock declined 18.55% with the market. The institutional investor held 100,000 shares of the biological products (no diagnostic substances) company at the end of 2018Q2, valued at $4.85 million, down from 850,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc (Call) for a number of months, seems to be less bullish one the $2.19B market cap company. The stock increased 2.22% or $1.03 during the last trading session, reaching $47.5. About 255,178 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since August 13, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 9 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Acceleron Pharma had 10 analyst reports since February 26, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Credit Suisse given on Friday, June 29. As per Thursday, March 1, the company rating was maintained by Citigroup. The rating was initiated by Oppenheimer on Tuesday, May 22 with “Hold”. Morgan Stanley downgraded Acceleron Pharma Inc. (NASDAQ:XLRN) on Friday, July 13 to “Equal-Weight” rating. The firm has “Neutral” rating given on Tuesday, July 10 by PiperJaffray. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Buy” rating by H.C. Wainwright on Wednesday, March 28. Barclays Capital maintained the shares of XLRN in report on Wednesday, February 28 with “Overweight” rating. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Overweight” rating given on Monday, February 26 by JP Morgan. Goldman Sachs upgraded the shares of XLRN in report on Friday, June 29 to “Neutral” rating. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Buy” rating by H.C. Wainwright on Wednesday, February 28.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company has market cap of $2.19 billion. The Company’s therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. It currently has negative earnings. The firm is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Benzinga.com which released: “Acceleron Pharma Q2 Earnings Preview” on August 02, 2018, also Streetinsider.com with their article: “Acceleron Pharma (XLRN) Reports Preliminary Results from Part 1 of ACE-083 Phase 2 Trial in Patients with Charcot …” published on July 23, 2018, Benzinga.com published: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” on July 28, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Businesswire.com and their article: “Acceleron Reports Second Quarter 2018 Operating and Financial Results” published on August 02, 2018 as well as Fool.com‘s news article titled: “Here’s Why Acceleron Pharma Inc. Lost 10.2% in July” with publication date: August 04, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.